Can PDRN Replace Tretinoin for Women Over 60?

📅 April 27, 2026👤 Restorative and Medical Skincare Researcher Simon Finch⏱ 14 min read

Can PDRN Replace Tretinoin for Women Over 60?

The comparison with retinoids is inevitable. For decades, retinoids — tretinoin (Retin-A), tazarotene (Tazorac), and their over-the-counter cousin retinol — have been the gold standard for anti-aging treatment. They are among the most rigorously studied ingredients in dermatology, with decades of clinical evidence supporting their ability to reduce fine lines, improve skin texture, and stimulate collagen production.

But retinoids have a problem that becomes increasingly severe with age: they are irritating, and postmenopausal skin is particularly vulnerable to retinoid dermatitis. The dryness, peeling, redness, and stinging that many women experience with retinoids are not signs that the product is "working" — they are signs of a chemical irritant reaction. For a woman over 60 whose skin barrier is already compromised by decades of aging and the hormonal changes of menopause, this irritation can be intolerable.

PDRN and retinoids work through completely different mechanisms. Retinoids are signalling molecules that bind to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in the nucleus, activating specific gene expression programmes. PDRN is a substrate that provides nucleotide building blocks for DNA repair and cellular maintenance. One tells the cell what to do; the other gives the cell the materials to do it. They are not competitors. They are complementary tools for different stages of the aging process and different aspects of skin health.

The question is not which one is better. The question is which one is right for you, at your age, with your skin type and sensitivity profile. And in many cases, the answer may be both.

How Retinoids Work: The Nuclear Receptor Pathway

Retinoids are derivatives of vitamin A (retinol). The most potent form is all-trans retinoic acid (ATRA), also known as tretinoin. When applied to the skin, retinol and retinaldehyde must be converted to ATRA through a two-step enzymatic process before they become active. Tretinoin, being already in the active form, works immediately upon application.

The Signalling Cascade

ATRA enters the cell by diffusing across the cell membrane — its small, lipophilic structure allows it to pass through the lipid bilayer without the need for a transporter. Once inside the cytoplasm, it binds to cellular retinoic acid-binding proteins (CRABPs), which chaperone it to the nucleus. In the nucleus, ATRA binds to retinoic acid receptors (RAR-α, RAR-β, RAR-γ), which form heterodimers with retinoid X receptors (RXR-α, RXR-β, RXR-γ).

The RAR-RXR heterodimer binds to specific DNA sequences called retinoic acid response elements (RAREs) in the promoter regions of target genes. When ATRA is bound, the heterodimer recruits coactivator proteins that modify chromatin structure — through histone acetylation and other modifications — making the target genes accessible for transcription.

This process activates or represses hundreds of genes. Among the most important for anti-aging are those encoding collagen type I and type III, which are upregulated, and those encoding matrix metalloproteinases (MMPs), which are downregulated. The net effect is a shift in the balance of the extracellular matrix toward synthesis and away from degradation.

What Retinoids Do Well

The evidence for retinoids in photoaged skin is strong. Kafi and colleagues (2007) conducted a landmark study showing that topical retinol (0.4%) significantly improved the appearance of naturally aged skin, with biopsies confirming increased collagen synthesis. After 24 weeks of treatment, retinol-treated skin showed a statistically significant reduction in fine wrinkles and an increase in dermal collagen production.

Retinoids also normalise epidermal differentiation — they reduce the cohesiveness of corneocytes in the stratum corneum, promoting a smoother, more even skin surface. They inhibit melanosome transfer, which helps with hyperpigmentation. And they stimulate glycosaminoglycan production, improving skin hydration and plumpness.

These effects are real and well-documented. For women who can tolerate them, retinoids remain one of the most effective anti-aging interventions available.

The Dark Side: Retinoid Dermatitis

But retinoids have a well-characterised side effect profile. Retinoid dermatitis — the constellation of dryness, peeling, erythema, and stinging — affects a significant proportion of users. In the Kafi study, 44% of retinol users experienced erythema compared with 18% of controls. With prescription-strength tretinoin, the rates are higher: some studies report irritation in 60–90% of users during the first weeks of treatment.

The mechanism of retinoid dermatitis is not fully understood, but it appears to involve several factors. Retinoids accelerate epidermal turnover, causing a transient thinning of the stratum corneum — the skin's protective barrier. They also trigger an inflammatory response through the activation of AP-1 transcription factors, which drive the expression of pro-inflammatory cytokines. And they disrupt the lipid bilayers of the stratum corneum, impairing barrier function.

For postmenopausal women, these effects are magnified. The skin barrier is already thinner and more fragile due to oestrogen loss. Ceramide levels in the stratum corneum are reduced by up to 30%. The rate of epidermal turnover has slowed. The inflammatory response to irritants is amplified due to the chronic low-grade inflammation of aging (inflammaging). What might be a mild irritation in a 30-year-old can be a significant reaction in a 60-year-old.

How PDRN Works: A Fundamentally Different Mechanism

PDRN operates through pathways that are entirely distinct from retinoids. While retinoids signal through nuclear receptors to change gene expression, PDRN provides the molecular substrates that cells use for their own maintenance and repair processes. This difference in mechanism has profound implications for tolerability, efficacy, and complementarity.

The Nucleotide Supply Mechanism

PDRN is a mixture of deoxyribonucleotides — the building blocks of DNA. When applied topically, it is broken down by enzymes in the skin into individual deoxyribonucleosides, which are then taken up by skin cells and converted into deoxyribonucleotide triphosphates (dNTPs) — the active form used for DNA synthesis and repair.

This mechanism is not pharmacological; it is nutritional. PDRN does not bind to receptors or activate signalling pathways to change cell behaviour. It simply provides raw materials that cells use to maintain their own DNA, support their mitochondria, and sustain their normal functions.

Kim and colleagues (2022) demonstrated that the activity of the nucleotide salvage pathway — the process by which cells recycle nucleotides — decreases by approximately 40% in aged human dermal fibroblasts compared with young fibroblasts. This means that older skin cells have a reduced capacity to maintain their own nucleotide pools, making them vulnerable to accumulating DNA damage and declining function. PDRN compensates for this deficit by providing exogenous nucleotides.

The Adenosine Signalling Mechanism

In addition to its nucleotide supply role, PDRN has an indirect signalling effect through adenosine. Deoxyadenosine, one of the nucleosides generated from PDRN breakdown, is converted to adenosine, which binds to the A2A adenosine receptor on skin cells. This receptor activates the cAMP/PKA signalling cascade, which has anti-inflammatory effects through the inhibition of NF-κB.

PDRN's adenosine-mediated anti-inflammatory effects are relevant in the comparison with retinoids because retinoid-induced inflammation is a significant contributor to retinoid dermatitis. By activating the A2A receptor and suppressing NF-κB, PDRN may reduce the inflammatory response that makes retinoids difficult to tolerate.

Lee and colleagues (2021) mapped adenosine receptor expression in aged human skin and found that the A2A receptor is expressed on both fibroblasts and keratinocytes, with maintained expression levels in older skin. This means the anti-inflammatory benefits of PDRN-derived adenosine signalling are available throughout the postmenopausal period.

Why Retinoid Tolerance Declines With Age

The challenge of retinoid use in women over 60 is not just about sensitivity — it is about the fundamental changes in skin biology that occur with age and after menopause. These changes affect every aspect of how the skin responds to topical treatments, including retinoids.

Barrier Function Decline

The skin barrier — the stratum corneum — becomes thinner and more porous with age. Transepidermal water loss (TEWL), a measure of barrier integrity, increases by approximately 30% between ages 40 and 80. This means that the skin loses more water and is less able to keep irritants out.

When a retinoid is applied to a compromised barrier, it penetrates more deeply and more rapidly than intended. This increased penetration amplifies both its therapeutic effects and its irritant effects. A concentration that would be well-tolerated on a healthy 30-year-old barrier may cause significant irritation on a 60-year-old barrier.

PDRN can help here. Sohn and colleagues (2023) demonstrated that topical PDRN significantly accelerated skin barrier recovery after controlled disruption, reducing TEWL and accelerating re-epithelialisation. By improving barrier function, PDRN may help the skin tolerate retinoids better.

Inflammatory Tone

As we discussed in the context of inflammaging, aged skin has a higher baseline level of inflammation. Pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) are elevated, and the transcription factor NF-κB shows increased activity. This means that any additional inflammatory stimulus — including a retinoid — will trigger a larger response in aged skin than in young skin.

PDRN's A2A-mediated anti-inflammatory effects may counteract this, reducing the baseline inflammatory tone and making the skin less reactive to retinoid-induced irritation.

Reduced DNA Repair Capacity

Retinoids accelerate epidermal turnover, which places increased demands on the skin's repair machinery. New keratinocytes must be produced more rapidly, and the DNA of these cells must be protected and maintained. In aged skin, where dNTP pools are depleted and DNA repair capacity is compromised, this increased demand may exceed the skin's capacity to cope.

PDRN provides the nucleotides needed to support increased DNA repair demands, potentially allowing the skin to handle the accelerated turnover induced by retinoids without accumulating damage.

Clinical Comparison: What the Evidence Shows

Direct head-to-head comparisons of PDRN and retinoids in the same population are limited, but the available evidence provides useful insights.

Chung and colleagues (2022) conducted a randomised controlled trial of topical PDRN in 76 postmenopausal women, measuring skin elasticity, hydration, and density over 12 weeks. The improvements were statistically significant and clinically meaningful. While no direct comparison with a retinoid arm was included, the magnitude of improvement in skin elasticity — approximately 18% increase from baseline — is comparable to what has been reported in retinoid studies in similar populations.

Critically, the tolerability profile was excellent. The reported incidence of irritation in the PDRN group was approximately 8%, with no cases of severe dermatitis. This contrasts sharply with retinoid studies, where irritation rates of 40–90% are typical.

The choice between PDRN and retinoids — or their combination — depends on individual goals, sensitivity, and tolerance. The table below illustrates the key considerations for women over 60.

Can They Be Used Together?

The question that naturally arises is whether PDRN and retinoids can be combined. The answer, based on their complementary mechanisms of action, is yes — and there are good reasons to do so.

Why Combining Makes Mechanistic Sense

Retinoids and PDRN address different aspects of the aging process. Retinoids stimulate collagen production and cell turnover through gene activation. PDRN supports DNA repair, mitochondrial function, and anti-inflammatory defence through nucleotide supply and adenosine signalling. These are not conflicting mechanisms; they are complementary.

In fact, PDRN may help mitigate some of the undesirable effects of retinoids. By supporting barrier repair (Sohn et al., 2023) and reducing inflammation through A2A receptor activation, PDRN may allow postmenopausal women to tolerate retinoids at concentrations that would otherwise be too irritating.

Additionally, the accelerated cell turnover induced by retinoids places increased demands on cellular repair machinery. The new keratinocytes produced in response to retinoid treatment need to maintain their DNA integrity in the face of ongoing environmental damage. PDRN provides the nucleotide substrates needed to support this increased repair demand.

A Practical Combined Protocol

For women over 60 who want to use both ingredients, here is an evidence-informed approach:

Start with PDRN alone. Begin by applying a PDRN serum twice daily for 4–8 weeks. This allows the skin barrier to improve and establishes a baseline of nucleotide support and anti-inflammatory protection. During this period, many women find that their skin becomes less reactive overall.

Introduce retinoids gradually. After the PDRN adaptation period, introduce a low concentration of retinol (0.1–0.3%) or tretinoin (0.01–0.025%) on alternate nights, applied after the PDRN serum. The PDRN applied in the morning will have supported barrier function and reduced inflammatory tone, potentially improving retinoid tolerance.

Use PDRN in the morning, retinoid at night. A practical split is to apply PDRN serum in the morning (followed by moisturiser and sunscreen) and a low-concentration retinoid at night (followed by a barrier-supporting moisturiser). This gives the skin the benefits of both ingredients while minimising the potential for irritation.

Monitor and adjust. If irritation develops, reduce the frequency of retinoid application to once every third night or switch to a lower concentration. You can also apply the PDRN serum before the retinoid at night, as the nucleotide support may have a buffering effect against irritation.

When to Choose One Over the Other

For women who cannot tolerate any concentration of retinoid — and this is not uncommon after 60 — PDRN alone is a viable alternative. While PDRN does not produce the dramatic cell turnover that retinoids do, its effects on skin elasticity, hydration, density, and barrier function are clinically meaningful and accompanied by excellent tolerability.

For women who tolerate retinoids well and are seeing good results, adding PDRN may provide additional benefits that retinoids cannot: DNA repair support, mitochondrial health, and anti-inflammatory protection. This combination may produce better long-term results than either ingredient alone.

For women who have never tried either ingredient and are just beginning to build an anti-aging routine, starting with PDRN is the gentler entry point. Once the skin has adapted to PDRN and barrier function has improved, introducing retinoids at low concentrations may be better tolerated.

The Concept of "Retinoid Impatience" in Older Skin

One underappreciated aspect of retinoid use in women over 60 is the gap between treatment expectations and biological reality. The retinoid "purge" — the initial worsening of skin appearance as cell turnover accelerates and brings underlying congestion to the surface — typically lasts 4–8 weeks. This is followed by a 12–24 week period of gradual improvement.

But postmenopausal skin turns over more slowly than young skin. The epidermal turnover rate decreases by approximately 30–50% between ages 20 and 80. This means that the effects of retinoids — which depend on accelerating this slow turnover — develop more slowly in older skin. A woman of 60 may need 16–20 weeks to see results that a 30-year-old would see in 8–12 weeks.

This slow response, combined with the higher risk of irritation, creates a frustrating dynamic: older women are more likely to experience the negative effects of retinoids and less likely to experience the positive effects, at least within the typical timeframe of clinical trials.

PDRN may offer an advantage here. Its effects on skin elasticity and barrier function develop gradually over 8–12 weeks, but they do so without a "purge" period and without the initial worsening that characterises retinoid use. The trajectory is one of steady, progressive improvement rather than the "worse before better" pattern of retinoids.

References